Related Experiment Video

Updated: Jul 13, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Serum hyaluronic acid as a marker of hepatic fibrosis

Jawwad Anis Khan1, Farooq Ahmad Khan, Muhammad Dilawar

  • 1Department of Pathology, CMH, Rahim Yar Khan. jawwad186@yahoo.com

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|July 12, 2007
PubMed

Insights

Serum hyaluronic acid (HA) is a valuable non-invasive marker for detecting liver fibrosis and cirrhosis. Elevated HA levels strongly correlate with the progression of liver fibrosis, indicating its utility in assessing liver disease severity.

Area of Science:

  • Hepatology
  • Biochemistry
  • Diagnostic Markers

Background:

  • Liver fibrosis and cirrhosis are significant causes of morbidity and mortality worldwide.
  • Accurate assessment of liver fibrosis is crucial for patient management and treatment decisions.
  • Non-invasive biomarkers are needed to complement or replace liver biopsy for fibrosis staging.

Purpose of the Study:

  • To evaluate serum hyaluronic acid (HA) as a biochemical marker for hepatic fibrosis and cirrhosis.
  • To correlate serum HA levels with the degree of liver fibrosis and cirrhosis.

Main Methods:

  • A comparative cross-sectional study was conducted involving 100 patients with chronic liver disease and 50 healthy controls.
  • Serum hyaluronic acid (HA) levels were measured and compared between patients and controls.
  • Liver biopsies were used to stage hepatic fibrosis (stages 0-4).

Main Results:

  • Mean serum HA levels were significantly higher in patients with chronic liver disease (189+/-98 mg/L) compared to healthy controls (21+/-10 mg/L) (p < 0.001).
  • Serum HA concentration showed a strong positive correlation with the stage of liver fibrosis, with the highest levels observed in stage 4 fibrosis (cirrhosis) (p < 0.001).
  • At a cutoff of 60 mg/L, serum HA demonstrated a sensitivity of 78.4% and specificity of 80.9% for detecting liver fibrosis.

Conclusions:

  • Serum hyaluronic acid (HA) is a reliable non-invasive biomarker for assessing liver fibrosis.
  • Increasing serum HA levels are indicative of progressive liver fibrosis and cirrhosis.
  • Serum HA offers a valuable tool for the non-invasive diagnosis and staging of liver fibrosis.
Abstract

More Related Videos

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...